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Abstract Certain nuclear morphometric features
measured in breast tumor tissue have been shown to
predict the prognosis of breast cancer patients. How-
ever, the application of these features to predicting risk
of breast cancer development has received little atten-
tion. We conducted a case-control study to evaluate
nuclear morphometric features in benign breast tissue
in association with subsequent breast cancer risk. The
study was nested within a cohort of 4,888 women with a
histopathologic diagnosis of benign breast disease
(BBD) and involved 61 cases and 71 controls, amongst
whom there were 53 matched case-control sets. Condi-
tional logistic regression models were ﬁtted to assess
various measurements of nuclear size and nuclear shape
factors in relation to subsequent breast cancer risk. In
multivariate analysis, subsequent breast cancer risk was
positively associated with a nuclear shape factor that
takes the shortest nuclear axis and the longest nuclear
axis into consideration simultaneously (highest quartile
versus lowest 3 quartiles: odds ratio = 3.07, 95% conﬁ-
dence limits = 1.61, 5.84). In contrast, there was no
alteration in subsequent breast cancer risk in associa-
tion with nuclear size features and other shape factors.
In conclusion, our study results suggest that the shape
factor that takes both the shortest nuclear axis and the
longestnuclearaxisintoconsiderationmightbeofvalue
to predict subsequent development of breast cancer
among women with BBD.
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Introduction
Benign breast disease (BBD), in addition to certain
hormonal, anthropometric, and lifestyle factors, is a
well-established risk factor for breast cancer [1, 2].
However, BBD comprises a broad spectrum of histo-
logical entities [3]. Both epidemiologic and experi-
mental studies suggest that non-atypical and atypical
proliferative changes represent successive steps pre-
ceding the development of in situ cancer and then
invasive carcinoma of the breast [4]. However, only a
small fraction of women will eventually develop breast
cancer after their diagnosis of BBD [5]. Therefore, it is
important to differentiate BBD patients with a high
risk of subsequent development of breast cancer from
those with a low risk. Our understanding regarding this
issue, however, is rather limited, although previous
studies have suggested that factors such as type of
histological subtype (e.g., atypical hyperplasia), men-
opausal status, and family history of breast cancer,
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Computerized image analysis and morphometry can
quantify a number of nuclear morphometric features
such as nuclear size, nuclear shape, and chromatin
texture [7]. The evaluation of these features may
facilitate the diagnosis and management of breast
cancer patients [8–10]. Indeed, certain nuclear mor-
phometric features measured in breast tumor tissue
have been shown to predict the prognosis of breast
cancer patients [11–15]. Furthermore, a study by
Mommers et al. [16] observed that normal breast tissue
or usual ductal hyperplasia harbored nuclear morpho-
metric changes that might be used to predict sub-
sequent development of breast cancer. In the study
reported here, we conducted a nested case-control
study to evaluate whether nuclear morphometric fea-
tures as evaluated in tissue sections of BBD may be
related to the risk of subsequent breast cancer among
patients with BBD.
Methods
Study population
The present investigation was undertaken using histo-
logical sections from a previous case-control study
nested within the cohort of 4,888 women in the
Canadian National Breast Screening Study (NBSS)
who were diagnosed histopathologically with BBD
during the active follow-up phase of the NBSS [17].
The NBSS is a multi-center randomized, controlled
trial of screening for breast cancer among 89,835
women aged 40–59 years at recruitment. The design of
the NBSS and population characteristics have been
described in detail elsewhere [18, 19]. Recruitment
took place between 1980 and 1985, and study subjects
were followed actively until 1988. Eligibility for the
study was restricted to women with no history of breast
cancer (in situ or invasive). The NBSS was approved by
the appropriate Institutional Review Boards, and the
study described here involved the analysis of material
and data from that study in accordance with the ap-
proved study design. Informed consent was obtained
from all study participants.
Diagnosis of BBD
In the NBSS, women who had clinical or radiologic
evidence of breast lesion underwent either a needle
aspiration or a biopsy. Diagnosis of BBD was per-
formed by a reference pathologist. Our study was
restricted to women who had no evidence of either in
situ or invasive breast cancer on their initial surgical
biopsy. Women with a history of BBD were not
excluded from the analyses. During the follow-up
period, we identiﬁed 4,888 women with a histopatho-
logic diagnosis of BBD, who were followed up for the
subsequent development of breast cancer.
Selection of cases and controls
Incident cases of breast cancer were ascertained by
record linkage with the provincial cancer registries, and
death clearance was performed by linkage to the
Canadian National Mortality Database [18, 19]. The
dates of the linkages varied by province, ranging from
late 1988 to early 1991. A total of 16 subjects with
ductal carcinoma in situ and 76 subjects with invasive
carcinoma were ascertained among the cohort of
women with BBD. Potential control subjects were
women with BBD who had not developed breast can-
cer (but were alive at) by the date of diagnosis of the
corresponding case subject. Five controls were selected
randomly (with replacement) for each case from those
non-cases available within strata deﬁned by screening
center, NBSS study arm, year of birth (if possible to the
nearest year, and mostly within 2 years), and age at
diagnosis of BBD. For the study reported here, 61 case
subjects and 71 control subjects (including 53 matched
case-control sets) were included.
Questionnaire
Upon enrollment in the NBSS, all participants com-
pleted a questionnaire that sought information on
demographic characteristics and risk factors for breast
cancer, including menstrual and reproductive histories
and family history of breast cancer.
Morphometry
Morphometric measurements were performed on H&E
stained slides, using the QPRODIT interactive video-
overlay system (Leica, Cambridge, UK). About 50
nuclei were selected in the most representative areas of
the slide (selected by a breast pathologist), and their
contours were traced manually using a 100· objective
(ﬁnal magniﬁcation about 3,000·)[ 20]. Mean and stan-
dard deviation of nuclear area, perimeter, diameter,
shortestaxis,longestaxis,andaxisratiowerecalculated,
aswellasdifferentshapefactors.Theshapefactorswere
calculated by the following formulas: Form_AR = (1/
4) * pi * longest axis * shortest axis; Form_PE =
4 * pi * area/(perimeter squared); Form_NCI =
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squared/4 * pi * area; and Roundness = perimeter/
(2*sqrt (pi * area)). All morphometric assessments
were performed by one observer without knowledge of
patient outcome.
Statistical analysis
Morphometric measurements were ﬁrst compared
between cases and controls using Student’s t-test.
Subsequently, the measurements were categorized by
quartiles and then odds ratios (OR) and 95% conﬁ-
dence limits (CLs) were calculated for the risk of
breast cancer for those in the highest quartile level
compared to that for those in the lowest 3 quartile
levels using conditional logistic regression. In multi-
variate analyses, we controlled for age at menarche
(<13, 13, 14+), age at ﬁrst live birth (nulliparous, <23,
23–26, 27+), menopausal status (pre-, peri-, post-), oral
contraceptive use (ever versus never), postmenopausal
estrogen use (ever vs. never), body mass index (<25,
25+), family history of breast cancer, and the presence
of hyperplasia in the benign tissue. All statistical
analyses were performed in SAS 9.1 (SAS Institute,
Cary, NC). P-values were two-sided.
Results
Table 1 summarizes the distribution of selected char-
acteristics among the cases and controls. Overall, few
differences between the cases and controls were
observed for age at menarche, age at ﬁrst live birth,
menopausal status, oral contraceptive use, postmeno-
pausal estrogen use, body mass index, family history of
breast cancer, and the presence of hyperplasia in
benign tissue.
There was little difference between the cases and
controls with respect to nuclear morphometric features
including mean area, standard deviation (SD) of area,
perimeter, diameter, shortest axis, and longest axis, as
well as such shape factors as Form_PE, Form_NCI,
contour, and roundness (Table 2). In contrast, the
shape factor Form_AR was greater among cases than
among controls. Furthermore, subjects with hyperpla-
sia had greater measures of some nuclear size features
including mean area, SD of area, perimeter, diameter,
and longest axis, and the shape factor Form_AR than
did subjects without hyperplasia (data not shown).
Quartile analyses revealed that subsequent breast
cancer risk was increased in association with the shape
factor Form_AR, but not with the other nuclear mor-
phometric measurements (Table 3). Compared to
BBD subjects with Form_AR equal to or less than
0.986, subjects with Form_AR greater than 0.986 had a
more than three-fold increased risk of developing
breast cancer subsequently (OR = 3.07, 95%CL =
1.61, 5.84). When the analyses were repeated using
unconditional logistic regression, which enabled all the
available cases and controls to be included, the results
did not change substantially.
Discussion
We found that breast cancer risk in women with BBD
was positively associated with the shape factor For-
m_AR, a measurement that takes the shortest nuclear
axis and the longest nuclear axis into consideration
simultaneously. In contrast, there was no alteration in
risk in association with nuclear area, SD of nuclear
area, nuclear perimeter, nuclear diameter, shortest
nuclear axis, longest nuclear axis, and other shape
Table 1 Distribution of selected characteristics among breast
cancer cases and non-cases
N (%) P-value
Cases Controls
Age at menarche
<13 30 (49) 26 (37) 0.29
13 13 (21) 22 (31)
14+ 18 (30) 23 (32)
Age at ﬁrst live birth
Nulliparous 11 (18) 9 (13) 0.84
<23 22 (36) 29 (41)
23–26 19 (31) 23 (32)
27+ 9 (15) 10 (14)
Menopausal status
Pre- 30 (49) 31 (44) 0.71
Peri- 9 (15) 14 (20)
Post- 22 (36) 26 (36)
Ever used oral contraceptives
Yes 35 (57) 42 (60) 0.76
No 26 (43) 28 (40)
Missing 0 1
Ever used postmenopausal estrogens
Yes 15 (25) 15 (22) 0.70
No 46 (75) 54 (78)
Missing 0 2
Body mass index (kg/m
2)
<25 32 (53) 41 (58) 0.42
25– < 30 27 (44) 25 (35)
30+ 2 (3) 5 (7)
Family history of breast cancer
Yes 23 (38) 28 (39) 0.84
No 38 (62) 43 (61)
Hyperplasia in benign tissue
Absent 34 (59) 47 (68) 0.27
Present 24 (41) 22 (32)
Missing 3 2
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123factors. Although subjects with hyperplasia had greater
measures of Form_AR than did subjects without
hyperplasia, we adjusted for hyperplasia, suggesting
that the association with Form_AR is independent of
that due to the presence of hyperplasia.
Shape is one of the factors that pathologists use in
assessing nuclear atypicality. Shape factors have been
shown tohaveprognosticvalueinbreast cancer[21–23],
renal cell cancer [24], colorectal cancer [25], squamous
cell carcinoma of the larynx [26], melanoma [27], and
rhabdomyosarcoma [28]. Apparently, alterations in
nuclear shape can already be present at the earliest
stages of carcinogenesis. This has in the breast also been
shown for nuclear chromatin patterns [29].
To date, only one study has been published that
assessed morphometric features in association with
subsequent development of breast cancer among
women with BBD [16]. That study found positive
associations for mean nuclear area, nuclear diameter,
nuclear perimeter, and the longest nuclear axis, but no
associations for SD of the nuclear area and the shortest
nuclear axis; shape factors were not evaluated. How-
ever, potential confounding factors were not controlled
for. In contrast to these ﬁndings, nuclear size features
were not associated with risk in the present study,
which may perhaps be explained by differences in tis-
sue processing procedures.
Our case-control study was nested in a cohort of
patients with histopathologically conﬁrmed BBD and
our ﬁndings are likely to be internally valid. Biased
measurement of the study exposures was not likely a
source of error, given that the morphometric features
were assessed without knowledge of the patient
outcome status. Our study power, however, was limited
by the relatively small sample size, due to which we
were not able to evaluate modifying effects by well-
documented risk factors of breast cancer. Moreover,
residual confounding might still exist, although to
minimize confounding we controlled for menstrual and
reproductive history, exogenous estrogen use, body
Table 2 Comparison of nuclear morphometric features in
benign breast tissue between breast cancer cases and non-cases
Morphometric
measurements
Mean (standard deviation) P-
value
Cases
(n = 61)
Controls
(n = 71)
Mean nuclear area
(lm
2)
26.8 (7.5) 25.3 (7.2) 0.25
SD of nuclear
area (lm
2)
5.2 (1.8) 5.0 (1.6) 0.43
Nuclear perimeter
(lm)
19.7 (2.7) 19.3 (2.7) 0.37
Nuclear diameter
(lm)
5.8 (0.8) 5.6 (0.8) 0.23
Shortest nuclear
axis (lm)
4.8 (0.7) 4.6 (0.7) 0.16
Longest nuclear
axis (lm)
7.1 (1.0) 7.0 (1.0) 0.53
Axis ratio 1.5 (0.1) 1.6 (0.2) 0.15
Form_AR 0.984 (0.005) 0.981 (0.007) 0.0089
Form_PE 0.844 (0.037) 0.831 (0.045) 0.083
Form_NCI 3.874 (0.095) 3.909 (0.122) 0.071
Contour 1.198 (0.061) 1.221 (0.080) 0.068
Roundness 1.093 (0.027) 1.103 (0.034) 0.071
Table 3 Risk of Subsequent development of breast cancer in association with nuclear morphometric features
a
Morphometric measurements Cut-off value OR (95% CL)
Model 1
b Model 2
c
Mean nuclear area (lm
2) 31.2 1.28 (0.73, 2.25) 0.94 (0.50, 1.78)
SD of nuclear area (lm
2) 6.1 1.33 (0.76, 2.31) 1.11 (0.59, 2.07)
Nuclear perimeter (lm) 21.4 1.14 (0.70, 1.93) 0.85 (0.47, 1.55)
Nuclear diameter (lm) 6.3 1.29 (0.73, 2.27) 0.95 (0.50, 1.79)
Shortest nuclear axis (lm) 5.2 1.62 (0.92, 2.86) 1.18 (0.62, 2.26)
Longest nuclear axis (lm) 8.0 1.34 (0.75, 2.39) 0.95 (0.50, 1.81)
Axis ratio 1.6 0.59 (0.30, 1.17) 0.71 (0.33, 1.54)
Form_AR 0.986 2.45 (1.42, 4.22) 3.07 (1.61, 5.84)
Form_PE 0.867 1.22 (0.71, 2.08) 1.57 (0.83, 2.97)
Form_NCI 3.935 1.07 (0.58, 1.98) 1.18 (0.61, 2.27)
Contour 1.236 1.13 (0.61, 2.10) 1.22 (0.63, 2.35)
Roundness 1.110 1.07 (0.58, 1.98) 1.18 (0.61, 2.27)
a Analyses were conducted among 53 matched case-control sets by comparing the highest quartile versus the lowest 3 quartiles in
conditional logistic regression models
b Adjusted for matching variables
c Adjusted for matching variables, age at menarche (<13, 13, 14+), age at ﬁrst live birth (nulliparous, <23, 23–26, 27+), menopausal
status (pre-, peri-, post-), oral contraceptive use (ever vs. never), postmenopausal estrogen use (ever versus never), body mass index
(<25, 25+), family history of breast cancer, and the presence of hyperplasia in the benign tissue
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123mass index, and family history of breast cancer in
multivariate analyses.
In conclusion, our study results suggest that the
shape factor that takes both shortest nuclear axis and
longest nuclear axis into consideration might be of
value to predict subsequent development of breast
cancer among patients with BBD. Given the limita-
tions of our study, larger studies are warranted to
conﬁrm our study results.
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